Figure 1.
Non-volatile compounds of rice bran. Inpari 30 non-fermented (IPRNF); Inpari 30 fermented (IPRF); Cempo Ireng non-fermented (CINF); and Cempo Ireng fermented (CIF).
Burnout among oncology healthcare providers (HCPs) poses significant challenges to both personal well-being and patient care quality. To inform targeted interventions, this study assessed burnout prevalence and its predictors among HCPs in a tertiary cancer center in Jordan. A cross-sectional study was conducted from October 10, 2023, to April 14, 2024, using an online questionnaire available in both English and Arabic. The survey, distributed via email and social media, included the Maslach Burnout Inventory (MBI), Patient Health Questionnaire-9 (PHQ-9), and sociodemographic items. Descriptive statistics, binary logistic, and group comparisons analyzed the relationships between demographic/work characteristics, depression, and burnout. Of 996 respondents, 692 (69.4%) completed the survey. Most participants were male (54.6%) and Muslim (98.3%), with 41.6% aged under 30. Respondents included physicians (17.1%), nurses (28.0%), and other healthcare roles (54.9%). Burnout levels were high, with 75.7% reporting high emotional exhaustion (EE), 35.3% experiencing high depersonalization (DP), and 27.2% showing low personal accomplishment (PA). Binary logistic regression analysis identified significant predictors of high EE, including lower income (<500 JD ≈ 705 USD, p = 0.004), thoughts of quitting (p = 0.000), and lack of burnout training (p = 0.007). High DP was associated with a lack of hobbies (p = 0.003) and thoughts of quitting (p = 0.000), while low PA was linked to a higher patient caseload (p = 0.000). Elevated PHQ-9 scores, indicative of depression, were significantly correlated with increased burnout across all dimensions (p < 0.001). In conclusion, burnout is highly prevalent among oncology HCPs in Jordan, with strong associations between burnout and specific demographic and work-related factors. Targeted interventions emphasizing stress management, organizational support, and effective coping mechanisms are crucial to mitigate burnout and enhance job satisfaction among oncology staff.
Citation: Omar Shamieh, Waleed Alrjoub, Ghadeer Alarjeh, Khawlah Ammar, Mohammad Abu Hazim, Tayseer Shawash, Osama Zamel, Maysa Al-Hussaini, Majeda Al-Ruzzieh, Hikmat Abdel-Razeq, Asem Mansour. Prevalence and predictors of staff burnout at a tertiary cancer center in Jordan[J]. AIMS Public Health, 2025, 12(2): 470-490. doi: 10.3934/publichealth.2025026
| [1] | Thornthan Sawangwan, Chompoonuth Porncharoennop, Harit Nimraksa . Antioxidant compounds from rice bran fermentation by lactic acid bacteria. AIMS Agriculture and Food, 2021, 6(2): 578-587. doi: 10.3934/agrfood.2021034 |
| [2] | Santi Noviasari, Feri Kusnandar, Agus Setiyono, Slamet Budijanto . Antioxidant activity and inhibition of α-amylase and α-glucosidase in fermented black rice bran-based analog rice. AIMS Agriculture and Food, 2022, 7(1): 61-72. doi: 10.3934/agrfood.2022004 |
| [3] | Budi Suarti, Sukarno, Ardiansyah, Slamet Budijanto . Bio-active compounds, their antioxidant activities, and the physicochemical and pasting properties of both pigmented and non-pigmented fermented de-husked rice flour. AIMS Agriculture and Food, 2021, 6(1): 49-64. doi: 10.3934/agrfood.2021004 |
| [4] | Rita Khathir, Murna Muzaifa, Yunita, Marai Rahmawati . Study on the physicochemical and sensory profile of pliek-u: A traditional dried fermented coconut endosperm from Aceh, Indonesia. AIMS Agriculture and Food, 2023, 8(2): 534-549. doi: 10.3934/agrfood.2023028 |
| [5] | Nur Fajriani Suaib, Didah Nur Faridah, Dede Robiatul Adawiyah, Nuri Andarwulan . Semiquantification of volatile compounds and identification of potential volatile markers and dry aroma from robusta second-crack roasted coffee processed from several post-harvest processing. AIMS Agriculture and Food, 2025, 10(1): 74-96. doi: 10.3934/agrfood.2025005 |
| [6] | Sapta Raharja, Yogi Purna Rahardjo, Samsudin, Khaswar Syamsu . Aroma precursor enhancing in dried cocoa beans fermentation using enzyme and heat addition. AIMS Agriculture and Food, 2023, 8(2): 674-686. doi: 10.3934/agrfood.2023037 |
| [7] | Alexandros Tsoupras, Eirini A. Panagopoulou, George Z. Kyzas . Anti-inflammatory, antithrombotic and anti-oxidant bioactives of beer and brewery by-products, as ingredients of bio-functional foods, nutraceuticals, cosmetics, cosmeceuticals and pharmaceuticals with health promoting properties. AIMS Agriculture and Food, 2024, 9(2): 568-606. doi: 10.3934/agrfood.2024032 |
| [8] | Anderson de Moura Zanine, Breno de Moura Gimenez, Daniele de Jesus Ferreira, Michelle de Oliveira Maia Parente, Henrique Nunes Parente, Edson Mauro Santos, Glayciane Costa Gois, Fleming Sena Campos, Luana Milena Pinheiro Rodrigues, Jessica Maria de Sousa Oliveira, Nelquides Braz Viana, Daimy Salas Aguilar, George de Sousa Lima Paiva, Dilier Olivera Viciedo . Nutritional parameters of sheep fed diets based on grass silage with brewery residue and a concentrate with rice bran. AIMS Agriculture and Food, 2024, 9(4): 1049-1063. doi: 10.3934/agrfood.2024056 |
| [9] | Dody Dwi Handoko, Anisa Maharani Kaseh, Laras Cempaka, Wahyudi David, Bram Kusbiantoro, Afifah Zahra Agista, Yusuke Ohsaki, Hitoshi Shirakawa, Ardiansyah . Effects of household-scale cooking on volatile compounds, sensory profile, and hypotensive effect of Kenikir (Cosmos caudatus). AIMS Agriculture and Food, 2023, 8(1): 198-213. doi: 10.3934/agrfood.2023011 |
| [10] | Orbe Chamorro Mayra, Luis- Armando Manosalvas-Quiroz, Nicolás Pinto Mosquera, Iván Samaniego . Effect of fermentation parameters on the antioxidant activity of Ecuadorian cocoa (Theobroma cacao L.). AIMS Agriculture and Food, 2024, 9(3): 872-886. doi: 10.3934/agrfood.2024047 |
Burnout among oncology healthcare providers (HCPs) poses significant challenges to both personal well-being and patient care quality. To inform targeted interventions, this study assessed burnout prevalence and its predictors among HCPs in a tertiary cancer center in Jordan. A cross-sectional study was conducted from October 10, 2023, to April 14, 2024, using an online questionnaire available in both English and Arabic. The survey, distributed via email and social media, included the Maslach Burnout Inventory (MBI), Patient Health Questionnaire-9 (PHQ-9), and sociodemographic items. Descriptive statistics, binary logistic, and group comparisons analyzed the relationships between demographic/work characteristics, depression, and burnout. Of 996 respondents, 692 (69.4%) completed the survey. Most participants were male (54.6%) and Muslim (98.3%), with 41.6% aged under 30. Respondents included physicians (17.1%), nurses (28.0%), and other healthcare roles (54.9%). Burnout levels were high, with 75.7% reporting high emotional exhaustion (EE), 35.3% experiencing high depersonalization (DP), and 27.2% showing low personal accomplishment (PA). Binary logistic regression analysis identified significant predictors of high EE, including lower income (<500 JD ≈ 705 USD, p = 0.004), thoughts of quitting (p = 0.000), and lack of burnout training (p = 0.007). High DP was associated with a lack of hobbies (p = 0.003) and thoughts of quitting (p = 0.000), while low PA was linked to a higher patient caseload (p = 0.000). Elevated PHQ-9 scores, indicative of depression, were significantly correlated with increased burnout across all dimensions (p < 0.001). In conclusion, burnout is highly prevalent among oncology HCPs in Jordan, with strong associations between burnout and specific demographic and work-related factors. Targeted interventions emphasizing stress management, organizational support, and effective coping mechanisms are crucial to mitigate burnout and enhance job satisfaction among oncology staff.
Rice is a staple food in Indonesia, which is one of the largest rice producers in the world. According to BPS-Statistics Indonesia, rice production touched 54.60 million tons in 2019 [1]. Polished rice is the primary product of rice, of which rice bran is the main by-product, followed by rice husk and germ. Rice bran consists of 8-12 percent of the by-product from the rice milling process [2].
Rice bran is used mainly as animal feed in Indonesia. There are not many studies on bioactivity, especially using animal model of diseases. Several studies show the potency of rice bran as food, especially as a functional ingredient, due to its beneficial bioactive compound content. The active bioactive compounds of rice bran are γ-oryzanol, polyphenols, phytosterols, tocopherols, tocotrienols, adenosine, ferulic acid, and adenosine, which can function as antioxidants and chemopreventive agents, with properties of lowering blood pressure and regulating cholesterol synthesis [3,4,5,6] Further, in some pigmented rice cultivars, rice bran is the part where the pigment is concentrated. The well-known pigmented rice in Indonesia is black rice. Black rice bran has a higher total phenolic content (TPC), anthocyanins, flavonoids, and antioxidant activity than polished red and white rice bran [7].
Solid-state fermentation (SSF) is known to enhance the bioactive compounds of rice bran [8]. This method uses solid media for microbial growth. The advantages of SSF are avoidance of lipid hydrolysis, minimum water requirements, low risk of contamination, and high yield of fermentation product [9]. Earlier studies and our own showed that SSF, by using Rhizopus oligosporus, can increase TPC and antioxidant activity [10,11]. Further, our results showed that SSF with R. oligosporus offers the optimum fermentation conditions for rice bran in Inpari 30 and Cempo Ireng for 72 hours at 30 ℃ [11].
The non-volatile compounds in rice bran have been studied in varieties of Calrose, Dixiebelle, and Neptune [12,13]. 453 compounds were found, consisting of amino acids, carbohydrates, vitamins and cofactors, lipids, nucleotides, peptides, secondary metabolites, and xenobiotics. Other studies have shown that fermentation treatment affects the number and diversity of bioactive compounds of rice bran [14]. Based on these findings, the non-volatile compounds of fermented and non-fermented rice bran may differ between rice varieties. Research has not been carried out on the non-volatile compounds in fermented and non-fermented bran, especially for rice bran varieties in Indonesia. Therefore, the purpose of this study was to analyze and compare non-volatile compounds of fermented and non-fermented rice bran of two varieties -i.e., Inpari 30 (IPR30) and Cempo Ireng (CI)- and their blood pressure lowering activity, by using a spontaneously hypertensive animal model. The IPR30 cultivar, another Ciherang cultivar (white rice) widely consumed in Indonesia and CI black rice cultivar, a variety of local pigmented rice planted in Bogor-West Java, Indonesia, were studied in this regard.
The sample used in this study was brown rice IPR30 obtained from Indonesian Center for Rice Research, Indonesian Agency for Agricultural Research and Development, Ministry of Agriculture, Subang, West Java, Indonesia and paddy CI from the local farmer in Bogor, West Java, Indonesia. Paddy of CI was de-hulled by a Rice Machine-THU (Satake, Japan) to obtain brown rice. Two types of brown rice were polished by mini rice mill processing (Satake Grain Testing Mill, Hiroshima, Japan) as described previously [11]. The samples were divided into non-fermented IPR30 rice bran (IPRNF), fermented IPR30 rice bran (IPRF), non-fermented CI rice bran (CINF), and fermented CI rice bran (CIF).
R. oligosporus were obtained from the Indonesian Culture Collection, Research Center for Biology, the Indonesian Institute of Science, Cibinong, Indonesia. The R. oligosporus were asseverated on potato dextrose agar media. The preparation of the culture and fermentation process followed the method used in a previous study [11]. The fermented and non-fermented samples were freeze-dried using a freeze-dryer (Labconco, USA) before further analysis.
Sample extraction was done as described by [15,16], with modifications. Samples were dissolved in distilled water with 20% (w/v). The solutions were centrifuged (5223 x g, 10 minutes, 4 ℃) and then extracted by the solid phase extraction method. For every five mL of supernatant, one ml of lidocaine (internal standard) was added, resulting in 2.0083 µM of lidocaine in the supernatant. Thereafter, six ml of solution two was inserted into the cartridge (Oasis HLB 12 mL). Samples were vacuumed to remove their water and salt content. Samples were then eluted with methanol 5% and 1.5 mL were collected for analysis. For the animal study, the water extract of fermented RB was used by an oral single dose experiment.
Non-volatile compounds were analyzed using Ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), as described in [12] with modifications. The liquid chromatography instrument used in this study was Waters ACQUITY UPLC H-Class System with C18 column (1.8 µm, 2.1 × 100 mm) at 50 ℃, while the mass spectrometry was Xevo G2-S quadrupole time-of-flight mass spectrometry (QToF-MS/MS) with electrospray ionization spray (ESI) system. For MS, the ion positive mode was used between 70-1000 m/z. Before injection, samples were filtered with a 0.2 µm syringe filter. Five µL of the sample was injected with mobile phase (A), 0.1% formic acid in water and (B), 0.1% formic acid in methanol (0% B to 70% B for 4 minutes, 70-98% B for 0.5 minutes, 98% B for 0.9 minutes). The observed injection flow rate was 0.2 mL per minute for 23 minutes. Masslynx v4.1 was used to identify the non-volatile compounds in the sample. The non-volatile compound data were then cross-checked with MassBank, Human Metabolome Database (HMDB) and Kyoto Encyclopedia of Genes and Genomes (KEGG) data [13]. The relative concentration of non-volatile compounds in the sample were determined by comparing the percentage area between sample and internal standard (lidocaine), based on the concentration of internal standard. The relative concentration was then converted into ppm units.
The male SHRSP/Izumo strain (Japan SLC, Shizuoka, Japan) was used in these studies. The rats were housed in individual stainless-steel cages in a controlled atmosphere (temperature, 23 ± 2 ℃; humidity, 50 ± 10%; 12 h light-dark cycle) as per a previous study [4]. The Animal Research-Animal Care Committee approved the experimental plan for the present study of Tohoku University (2016AgA-024). The entire experiment was conducted following the guidelines issued by this committee and Japanese governmental legislation (2005). The water extract of fermented RB (CI and IPR30, 72 h fermentation) was used to determine the BP-lowering effect in SHRSP. The number of animals used in this study, concentration of the sample in the treated group, and control were similar to our previous study [11]. The blood pressure measurement was by the tail-cuff method with a BP meter as described in the previous study [4].
The data are described as the mean ± SD. One way analysis of variance using SPSS version 22.0 was performed by two-way analysis (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test for blood pressure study. The categorization of non-volatile compounds based on their relative concentration was analyzed by principal component analysis (PCA) with XLSTAT 2019.
The non-volatile compounds of fermented and non-fermented rice bran of Inpari 30 and Cempo Ireng are presented in Supplementary Table 1. These were classified into 36 secondary metabolites, 16 lipids, 8 amino acids, 7 vitamins and cofactors, 3 peptides, one carbohydrate, and one nucleotide (Figure 1). Fermentation of Inpari 30 and Cempo Ireng rice bran produced new compounds that were not found in the non-fermented samples.
The highest concentration of secondary metabolites found in IPRNF consisted of n, n-diethyl phenylacetamide (MS25), while in IPRF rice bran, the contents were dominated by 2-acetylpyrrole (MS29) and momilactone B (MS7). A study on n, n-diethyl phenylacetamide has shown that it can be used as an insect repellent [17] and 2-acetylpyrrole has hepatoprotective properties [18]. Several studies have shown momilactone B exhibiting inhibitory activities on α-amylase and α-glucosidase, as well as anti-cancer activities by increasing apoptosis in cancer cells [19,20]. In CINF rice bran, the dominant secondary metabolites were myrigalone A (MS36), kojic acid (MS9) and 4-methylbenzoic acid (MS11). Myrigalone A has been known to show antibacterial properties and kojic acid is a chelating agent produced during aerobic fungal fermentation [21].
The most abundant compounds from the lipid in IPRNF and IPRF were leukotriene A4 (LD8) and aminocaproic acid (LD6). The dominant lipid compounds in CINF and CIF were lacinilene C 7-methyl ether (LD2) and phytosphingosine (LD9) respectively. Lacinilene C 7-methyl ether is known to have antibacterial properties [22]. Phytosphingosine has shown anti-inflammatory and antibacterial properties in skin disorders, besides playing a role in transcription activation in peroxisome proliferator-activated receptor [23,24].
Amino acids with the highest concentration found in IPRNF and IPRF were norvaline (AA2) and l-phenylalanine (AA7) respectively. Norvaline is a byproduct of branched-chain amino acid synthesis, which can also act as arginase inhibitor [25]. L-phenylalanine is involved in neurotransmitters, hormones, and skin pigment synthesis in humans [26]. The highest concentration of amino acids in CINF and CIF were 3-methyldioxyindole (AA6) and indoleacrylic acid (AA8) respectively. Indoleacrylic acid has been known to be produced during tryptophan degradation.
The dominant compounds found in the vitamins and cofactors group in IPRNF and IPRF were trigonelline (VK5) and pantothenic acid (VK2) respectively. Trigonelline is found only in IPRNF rice bran and is involved in treating diabetes by lowering the blood glucose level, increasing insulin sensitivity, and decreasing lipid peroxidation [27]. Pantothenic acid is synthesized by R. oligosporus from β-alanine and pantoic acid [28]. The dominant compound in the vitamins and cofactors in CINF and CIF were nicotinic acid (VK1) and 7-aminomethyl-7-carbaguanine (VK6), respectively. Nicotinic acid prevents atherosclerosis by increasing high-density lipoprotein, and decreasing triglyceride level and oxidative stress [29].
Non-volatile compounds from the peptide group were detected only in the fermented samples. The most abundant peptide found in IPRF and CIF were phenylalanyl-isoleucine (PD3) and leucyl-isoleucine (PD2), respectively. According to an earlier study, Leucyl-isoleucine increases monocytes and platelet level in rats and stimulates AMPK phosphorylation [30,31].
Principal component analysis (PCA) was applied to compare the differences of quantum in non-volatile compounds among the samples. The PCA of non-volatile compounds is shown in Figure 2. Non-fermented rice bran samples (IPRNF and CINF) were located in a quadrant different from fermented rice bran (IPRF and CIF), indicating that fermentation influenced non-volatile compound production. Adenosine (NA) generally was found the most in non-volatile compounds across all the samples. In the fermented sample of Inpari 30, the level of n, n-diethyl phenylacetamide (MS25), indoleacrylic acid (AA8), and l-phenylalanine (AA7) were higher, compared to non-fermented rice bran. Other major non-volatile compounds found in IPRNF samples were leukotriene A4 (LD8) and trigonelline (VK5).
On the other hand, fermentation of the Cempo Ireng variety showed an increase in quercetin (MS15), isorhamnetin 7-glucoside (MS16), isorhamnetin (MS17), and nicotinic acid (VK1) levels. In Cempo Ireng samples, the non-volatile compounds with the highest concentration after adenosine were different. In CINF, it was myrigalone A (MS36), while CIF leucyl-isoleucine (PD2) and phenylalanyl-isoleucine (PD3) showed similar concentrations. These compounds are likely to have originated from arachidonic acid, nicotinic acid and nicotinamide, phenylalanine, tryptophan, and dipeptide metabolism. The major non-volatile compounds from each classification from PCA analysis are summarized in Figure 3. The list of non-volatile compounds and its statistical analyses shown in Supplementary Table 1 (Supplementary data).
Adenosine is a compound necessary for production of energy within the body, and is created from purine metabolism. As a phytochemical found in rice bran, adenosine has the effect of lowering blood pressure, helps to treat hyperlipidemia, increases insulin activity, and preventing hypertension in the stroke-prone spontaneously hypertensive rat (SHRSP) [5]. In humans, adenosine has neuromodulator and neuroprotective functions, reduces epilepsy, and regulates the sleep cycle [32,33,34].
Several studies of these compounds have shown them to have beneficial effects for the body, which includes lowering blood pressure, improving the immune and digestive systems, as well as having neuromodulator, neuroprotective, chemo preventive and antidiabetic properties. Further, other studies have also found that these bioactive compounds play a part in preventing gastric ulcer and improving hormone and melanin synthesis [26,27,30,32].
The proposed metabolic pathways found in rice bran are shown in Figure 4. Previous studies shown that rice bran has contained non-volatile compounds (12-14). Our study carried out non-volatile compound of fermented and non-fermented rice bran varieties in Indonesia. Pathways related to the compounds in the fermented and non-fermented Inpari 30 rice bran were the metabolism of valine and the citric acid cycle, respectively. Folate metabolism was found in fermented Cempo Ireng rice bran, while pentatonic acid, vitamin B6, and benzoxazinoid metabolism were found in non-fermented Cempo Ireng rice bran. Fermented versions of both fermented Inpari 30 and Cempo Ireng rice bran produced compounds from the metabolism of tyrosine, phenylalanine, pantothenic acid and dipeptide that was not detected in the non-fermented samples.
Non-volatile compounds in fermented Inpari 30 and Cempo Ireng rice brans were identified as metabolic pathways from tyrosine, phenylalanine, pantothenic acid, folic acid, dipeptide, terpenoid, and sphingolipid. The presence of dipeptide and amino acid compounds indicated that the samples were attributed to rice bran protein degradation by R. oligosporus-synthesized protease [35]. Similarly, metabolites of pantothenic and folic acid were also utilized by fungi, as they are components necessary for fungal metabolic activities [36]. Comparatively, compounds from sphingolipid metabolism are commonly found in fungal plasma membrane [37]. Fungi sphingolipids known to be involved in hyphal morphogenesis are produced during sphingolipid metabolism with serine and palmitoyl-CoA as its precursor [38,39], similar to the terpenoid found in fermented rice bran produced by the fungal mevalonate pathway [40].
This study also investigated whether fermented RB showed any blood pressure-lowering effects after administration of a single oral dose (40 mg/kg body weight) (Table 1). Twelve-week-old male SHRSP with a systolic blood pressure (sBP) of approximately 170 mmHg, were used in this study. The result showed that there was similar sBP of the control group before and after administration. The sBP showed a significant decrease after 6h administration of IPRF (p < 0.05), compared to the control group. A blood pressure lowering activity was also found as sBP was decreasing from 2 h after administration until the end of the study. This study was consistent with the previous study by using Inpari 30 fermented RB [11]. Further, this study also showed evidence of adenosine as one of the identified bioactive compounds in rice bran [5].
| Group | 0 h | 2 h | 4 h | 6 h |
| Control | 172.3 ± 13.1 | 172.0 ± 8.1 | 161.3 ± 6.5 | 168.0 ± 3.0 |
| CIF | 176.8 ± 9.1 | 175.3 ± 2.9 | 165.3 ± 13.3 | 166.8 ± 8.5 |
| Change b (%) | - | +1.9 | +2.4 | −0.7 |
| IPRF | 171.3 ± 5.0 | 152.3 ± 14.3 | 142.0 ± 12.4 | 141.5 ± 12.2* |
| Change b (%) | - | −12.9 | −13.6 | −18.7 |
| Note: a Values are given as means ± SD, n = 4. *A significantly different (p < 0.05) versus Control after statistical analysis by one-way analysis of variance using SPSS version 22 software (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test. | ||||
DownLoad:
CSV
This study strengthened the proposition that IPRF is a good source of functional ingredient that can be effective in decreasing hypertension in an animal model of metabolic syndrome-related diseases. Future studies are required to specify the IPRF mechanism of blood pressure-lowering activity and other functionalities in relation to metabolic diseases.
Different rice varieties and fermentation processes influence the concentration and types of non-volatile compounds in rice bran. Adenosine was found to have the greatest concentration of non-volatile compound in rice bran. Fermentation of rice bran samples from IPR30 and CI varieties generated compounds from tyrosine, phenylalanine, pentatonic acid, dipeptide, sphingolipid and terpenoid metabolism, which were not found in the non-fermented rice bran. Fermentation of rice bran can produce and enhance non-volatile compounds as anti-hypertensive effect in an animal model of hypertension. Further, this study found adenosine to be a useful marker for non-volatile compounds in rice bran.
We would like to thank to the Ministry Research and Technology/BRIN RI for research funding. The partial of the research was supported by a grant from the collaboration research of JSPS and DIKTI RI.
All authors declare no conflict of interest.
| Compounds | Codes | HMDB ID | Relative Concentrations (ppm) | Effects | References | |||
| Inpari 30 | Cempo Ireng | |||||||
| Non-fermented | Fermented | Non-fermented | Fermented | |||||
| (Amino acids) | ||||||||
| Meta-tyrosine | AA1 | 0059720 | ND | 0.0266* | ND | ND | Immunoprotective | [41] |
| Reduces metastasis | [42] | |||||||
| Norvaline | AA2 | 0013716 | 0.0253* | 0.0008* | ND | ND | Arginase inhibitor | [31] |
| N-Acetyltryptophan | AA3 | 0013713 | ND | 0.0039* | ND | ND | Antioxidant | [43] |
| 1H-Imidazole-1-acetic acid | AA4 | 0029736 | ND | ND | ND | 0.0033* | - | - |
| L-DOPA | AA5 | 0000181 | ND | ND | ND | 0.0050* | Treatment of Parkinson Dissease (by increasing dopamine levels in brain) | [44] |
| 3-Methyldioxyindole | AA6 | 0004186 | ND | ND | 0.0011 ± 0.0003 | ND | - | - |
| L-Phenylalanine | AA7 | 0000159 | ND | 0.2413 ± 0.2051a | ND | 0.0360 ± 0.0080b | Neurotransmitter synthesis, hormones and pigments synthesis | [26] |
| Indoleacrylic acid | AA8 | 0000734 | 0.0115*a | 0.1806 ± 0.1412b | ND | 0.0395 ± 0.0011a | Improves the instentines functions | [45] |
| (Carbohydrates) | ||||||||
| Succinic acid | KH | 0000254 | 0.0002* | ND | ND | ND | Antioxidant, Imrpove the immune and nervous functions | [46] |
| (Lipids) | ||||||||
| Cincassiol B | LD1 | 0036855 | ND | 0, 0208* | ND | ND | - | - |
| Lacinilene C 7-methyl ether | LD2 | 0036456 | 0.0129 ± 0.0015 | 0.0058* | 0.0134* | 0.0023* | Antimicrobial | [22] |
| Valdiic acid | LD3 | 0040980 | ND | 0.0088 ± 0.0108 | ND | ND | - | - |
| Prostaglandin C1(1-) | LD4 | 0062756 | 0.0102 ± 0.0029 | ND | 0.0090 ± 0.0017 | ND | - | - |
| 10-Oxo-11-octadecen-13-olide | LD5 | 0029786 | 0.0041* | ND | 0.0109* | ND | - | - |
| Aminocaproic acid | LD6 | 0001901 | ND | 0.0390* | ND | 0.0037* | Antifibrinolytic | [47] |
| L-Octanoylcarnitine | LD7 | 0000791 | ND | 0.0180* | 0.0091 ± 0.0052 | ND | - | - |
| Leukotriene A4 | LD8 | 0029016 | 0.0352 ± 0.0288 | 0.0131 ± 0.0063 | 0.0110* | ND | The parent molecule for the biosynthesis of all leukotrienes | [48] |
| Phytosphingosine | LD9 | 0004610 | ND | 0.0126*b | 0.0114 ± 0.0031a | 0.0049 ± 0.0042b | ● Anti-inlammatory and antibacterial in skin disorders | [31] |
| ● Activates the transcription activity on PPAR | [23] | |||||||
| (Ent-2alpha, 3beta, 15beta, 16beta)-15, 16-Epoxy-2, 3-kauranediol | LD10 | 0038688 | 0.0201 ± 0.0099b | ND | 0.0019*a | ND | - | - |
| Dehydroabietic acid | LD11 | 0031127 | 0.0263* | ND | ND | ND | ● Anti-inflammatory in obese people | [49] |
| ● Activates the SIRT1 enzymes | [50] | |||||||
| 13, 14-Dihydro-15-keto-PGE2 | LD12 | 0002776 | ND | ND | 0.0010* | ND | Increases the growth of pancreatic celss | [51] |
| 3-hydroxyundecanoyl carnitine | LD13 | 0061637 | ND | ND | 0.0102 ± 0.0031 | ND | - | - |
| Leukotriene C4 | LD14 | 0001198 | 0.0095* | ND | ND | ND | Lipid mediator for inflammation | [52] |
| 5-Hexyltetrahydro-2-furanoctanoic acid | LD15 | 0029018 | 0.0105* | ND | 0.0021* | ND | - | - |
| (Z)-13-Oxo-9-octadecenoic acid | LD16 | 0029796 | 0.0094* | 0.0072* | ND | ND | - | - |
| (Nucleotides) | ||||||||
| Adenosine | NA | 0000050 | 0.0838 ± 0.1053 | 0.4323 ± 0.1236 | 0.2119 ± 0.0142 | 0.3007 ± 0.1602 | ● Neuromodulator | [34] |
| ● Neuroprotective | [33] | |||||||
| ● Reduces epilepsy | [32] | |||||||
| ● Regulates the sleep cycle | [53] | |||||||
| ● Lowering blood pressure | [5] | |||||||
| (Secondary Metabolites) | ||||||||
| Cohumulone | MS1 | 0033981 | ND | 0.0052* | ND | ND | Aldo keto reductase inhibitors | [54] |
| 3-O-Methylmethyldopa | MS2 | 0142154 | ND | 0.0022 ± 0.0005 | ND | ND | - | - |
| 2, 6-Dimethoxy-4-propylphenol | MS3 | 0036226 | ND | 0.0007 ± 0.0001 | ND | ND | - | - |
| Alpha-curcumene | MS4 | 0059878 | ND | 0.0017±0.0004 | ND | ND | ● Antimicrobial | [55] |
| ● Induced apoptosis | [56] | |||||||
| Cuscohygrine | MS5 | 0030290 | ND | 0.0033* | 0.0051* | 0.0028* | - | - |
| 3-Tert-butyl-4-hydroxyanisole | MS6 | 0059925 | ND | 0.0015* | 0.0184* | ND | The building blocks of butylated hydroxyanisole (BHA) | [57] |
| Momilactone B | MS7 | 0036749 | ND | 0.0153* | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| ● Cancer chemopreventive | [19] | |||||||
| 2-Indolecarboxylic acid | MS8 | 0002285 | 0.0024* | ND | 0.0023* | ND | Antioxidant | [58] |
| Kojic acid | MS9 | 0032923 | 0.0061 ± 0.0016 | ND | 0.0103 ± 0.0010 | ND | ● Tyrosinase inhibitors | [59] |
| ● Immunomodulator | [9] | |||||||
| L-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid | MS10 | 0035665 | 0.0008* | ND | ND | ND | - | - |
| 4-Methylbenzoic acid | MS11 | 0029635 | 0.0010*a | ND | ND | 0.0385 ± 0.0103b | - | - |
| 2-Methylhippuric acid | MS12 | 0011723 | 0.0006* | ND | ND | ND | - | - |
| Momilactone A | MS13 | 0036748 | 0.0020* | ND | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| Coumarin | MS14 | 0001218 | 0.0009* | ND | ND | ND | ● Antimicrobial | [60) |
| ● Acetylcholinesterase (AChE) inhibitor | [61] | |||||||
| Quercetin | MS15 | 0005794 | ND | ND | 0.0050 ± 0.0031 | 0.0057 ± 0.0028 | ● Antioxidant | [62] |
| ● Decreases activation of dendytic celss for the treatment of inflammation, autoimmunity and transplantation | [61] | |||||||
| ● Antiviral activity against dengue fever | [63] | |||||||
| ● Lowering blood pressure in people with hypertension | [64] | |||||||
| ● Reduces symptoms of non-alcoholic fatty liver dissease | [65] | |||||||
| Isorhamnetin 7-glucoside | MS16 | 0029479 | ND | ND | 0.0089 ± 0.0050 | 0.0165 ± 0.0009 | Antioxidant | [66] |
| Isorhamnetin | MS17 | 0002655 | ND | ND | 0.0048* | 0.0121* | Treats cerebral vascular complications associated with diabetes | [67] |
| 2-Hydroxy-2-phenylpropanoic acid | MS18 | 0142137 | ND | ND | 0.0045 ± 0.0007a | 0.0029 ± 0.0013b | - | - |
| 2-Phenylpropionaldehyde dimethyl acetal | MS19 | 0032468 | ND | ND | ND | 0.0055 ± 0.0022 | - | - |
| Naringenin | MS20 | 0002670 | ND | ND | ND | 0.0037* | ● Hepatoprotector | [68] |
| ● Reduces TNF- α production | [69] | |||||||
| ● Anti-hyperglycemia | [70] | |||||||
| ● Cardioprotective | [71] | |||||||
| ● Antiviral activity against dengue fever | [72] | |||||||
| ● Inhibits the proliferation and migration of prostate cancer cells | [73] | |||||||
| Phenprocoumon | MS21 | 0015081 | ND | ND | ND | 0.0058* | ● Anticoagulant | [74] |
| Isovanillic acid | MS22 | 0060003 | ND | ND | 0.0042 ± 0.0011 | ND | ● Antibacterial | [75] |
| ● Antioxidant | [76] | |||||||
| Antimicrobial | [60] | |||||||
| 2, 6-Dimethoxybenzoic acid | MS23 | 0029273 | ND | ND | 0.0106* | ND | - | - |
| Benzoic acid | MS24 | 0001870 | ND | ND | 0.0009 ± 0.0003 | ND | Inhibits the growth of resistant bacteria | [77] |
| N, N-diethyl phenylacetamide | MS25 | 0032635 | 0.0090* | 0.0096* | 0.0066* | 0.0263* | Mosquitos repellent | [17] |
| Oryzalide B | MS27 | 0037592 | ND | ND | ND | 0.0053 ± 0.0032 | Antibacterial | [78] |
| Acetylvalerenolic acid | MS28 | 0035687 | ND | ND | ND | 0.0045* | - | - |
| MS29 | 0035882 | ND | 0.0309 | ND | ND | Hepatoprotector | [18] | |
| Dimboa-glc | MS30 | 0029710 | ND | ND | 0.0089 ± 0.0056 | ND | - | - |
| 2-Decylfuran | MS31 | 0032215 | ND | ND | ND | 0.0015 | - | - |
| Piperenol A triacetate | MS32 | 0041535 | ND | 0.0129* | ND | ND | - | - |
| Ginsenoyne G | MS33 | 0039589 | ND | ND | 0.0025 | ND | - | - |
| Acetylpterosin C | MS34 | 0030764 | 0.0053* | ND | ND | ND | - | - |
| 1, 3, 11-Tridecatriene-5, 7, 9-triyne | MS35 | 0034294 | ND | ND | 0.0160 | ND | - | - |
| Myrigalone A | MS36 | 0037245 | ND | ND | 0.0278* | 0.0256* | Antibacterial | [79] |
| (Vitamins dan cofactors) | ||||||||
| Nicotinic acid | VK1 | 0001488 | 0.0114 ± 0.0007 | ND | 0.0060 ± 0.0025 | 0.0076 ± 0.0009 | Increases HDL cholesterol and lowers triglycerides for the treatment of atherosclerosis | [29] |
| Pantothenic acid | VK2 | 0000210 | ND | ND | ND | 0.0028 ± 0.0010 | Substrates for the synthesis of coenzyme A and ACP (acyl carrier protein) | [80] |
| 2-Hydroxypyridine | VK3 | 0013751 | 0.0008* | ND | ND | ND | - | - |
| 4-Methyl-5-thiazoleethanol | VK4 | - | 0.0175 ± 0.0014 | ND | 0.0066 ± 0.0021 | ND | - | - |
| Trigonelline | VK5 | 0000875 | 0.0344 ± 0.0247 | ND | ND | ND | ● Increases cell sensitivity to anticancer and apoptotic drugs | [81] |
| ● Prevents gastric ulcer induced by indomethacin | [82] | |||||||
| ● Lowering blood sugar and lipid as well as increasing insulin sensitivity for diabetes | ||||||||
| ● Inhibits neurons loss in hypocampus | [83] | |||||||
| 7-Aminomethyl-7-carbaguanine | VK6 | 0011690 | ND | ND | ND | 0.0132* | - | - |
| Pyridoxal | VK7 | 0001545 | ND | ND | 0.0066 ± 0.0021 | ND | ● Cofactors in various amino acids metabolism | [84] |
| ● Maintains the nervous systems in infants | [85] | |||||||
| (Peptides) | ||||||||
| Leucyl-valine | PD1 | 0028942 | ND | 0.0222 ± 0.0162 | ND | ND | Increases the expression of glutathione peroxidase, antioxidants and cell protection agents | [86] |
| Leucyl-isoleucine | PD2 | 0028932 | ND | 0.0653 ± 0.0436 | ND | 0.0596 ± 0.0263 | Increases the stimulation of AMPK phosphorylation (5'-AMP protein kinase), monocytes, and platelets | [30] |
| Note: The presentation of the relative value data for the compounds comes from the calculation of the average relative area of the compound from 3 replications ± deviation standard; ND = Not Detected; * = compound obtained only in 1 replication; Numbers on the same line with different letters indicate significant differences (p < 0.05). | ||||||||
DownLoad:
CSV
| [1] |
Potter P, Deshields T, Berger J, et al. (2010) Compassion fatigue and burnout: Prevalence among oncology nurses. Clin J Oncol Nurs 14: E56-E62. https://doi.org/10.1188/10.CJON.E56-E62 
|
| [2] |
Chemali Z, Ezzeddine F, Gelaye B, et al. (2019) Burnout among healthcare providers in the complex environment of the Middle East: A systematic review. BMC Public Health 19: 1-21. https://doi.org/10.1186/s12889-019-7713-1
|
| [3] |
Abusanad A, Tayem YI, AlQarni WA, et al. (2021) Burnout in oncology: Magnitude, risk factors and screening among professionals from Middle East and North Africa (BOMENA study). Psychooncology 30: 736-746. https://doi.org/10.1002/pon.5624
|
| [4] |
Jarrad RA, Hammad S (2020) Oncology nurses' compassion fatigue, burnout, and compassion satisfaction. Ann Gen Psychiatry 19: 1-8. https://doi.org/10.1186/s12991-020-00272-9
|
| [5] |
Maslach C, Jackson SE (1981) The measurement of experienced burnout. J Organ Behav 2: 99-113. https://doi.org/10.1002/job.4030020205
|
| [6] |
Dewa CS, Loong D, Bonato S, et al. (2017) The relationship between physician burnout and quality of healthcare in terms of safety and acceptability: A systematic review. BMJ Open 7: e015141. https://doi.org/10.1136/bmjopen-2016-015141
|
| [7] |
Panagioti M, Geraghty K, Johnson J, et al. (2018) Association between physician burnout and patient safety, professionalism, and patient satisfaction: A systematic review and meta-analysis. JAMA Intern Med 178: 1317-1330. https://doi.org/10.1001/jamainternmed.2018.3713
|
| [8] |
Tawfik DS, Profit J, Morgenthaler TI, et al. (2019) Evidence relating health care provider burnout and quality of care. Ann Intern Med 171: 555-567. https://doi.org/10.7326/M19-1152
|
| [9] |
Han S, Shanafelt TD, Sinsky CA, et al. (2019) Estimating the attributable cost of physician burnout in the United States. Ann Intern Med 170: 784-790. https://doi.org/10.7326/M18-1422
|
| [10] |
Rotenstein LS, Torre M, Ramos MA, et al. (2018) Prevalence of burnout among physicians: A systematic review. JAMA 320: 1131-1150. https://doi.org/10.1001/jama.2018.12777
|
| [11] |
Elbarazi I, Loney T, Yousef S, et al. (2017) Prevalence of and factors associated with burnout among health care professionals in Arab countries: A systematic review. BMC Health Serv Res 17: 1-10. https://doi.org/10.1186/s12913-017-2319-8
|
| [12] |
Sipos D, Kunstár O, Kovács A, et al. (2023) Burnout among oncologists, nurses, and radiographers working in oncology patient care during the COVID-19 pandemic. Radiography 3: 503-508. https://doi:10.1016/j.radi.2023.02.008
|
| [13] |
Sipos D, Goyal R, Zapata T (2024) Addressing burnout in the healthcare workforce: Current realities and mitigation strategies. Lancet Reg Heal Eur 42: 100961. https://doi:10.1016/j.lanepe.2024.100961
|
| [14] |
Guveli H, Anuk D, Oflaz S, et al. (2015) Oncology staff: Burnout, job satisfaction and coping with stress. Psychooncology 24: 926-931. https://doi.org/10.1002/pon.3743
|
| [15] |
Alwatban L, Alageel MS, Alshehri LA, et al. (2024) The stigma of burnout impeding formal help: A qualitative study exploring residents' experiences during training. Adv Med Educ Pract 15: 333-342. https://doi:10.2147/AMEP.S453564
|
| [16] | King Hussein Cancer CenterAccreditations | KHCC, KHCC official website (2025). [cited 2025 April 07]. Available from: https://www.khcc.jo/en/accreditations |
| [17] |
Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16: 606-613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
|
| [18] |
AlHadi AN, AlAteeq DA, Al-Sharif E, et al. (2017) An Arabic translation, reliability, and validation of Patient Health Questionnaire in a Saudi sample. Ann Gen Psychiatry 16: 1-9. https://doi.org/10.1186/s12991-017-0155-1
|
| [19] | Maslach C, Jackson SE, Leiter MP (1997) The Maslach Burnout Inventory Manual. Evaluating Stress: A Book of Resources . Lanham: Scarecrow Press 191-218. |
| [20] | Sabbah I, Sabbah H, Sabbah S, et al. (2012) Burnout among Lebanese nurses: Psychometric properties of the Maslach Burnout Inventory-Human Services Survey (MBI-HSS). Health (Irvine Calif) 4: 644-652. https://doi:10.4236/health.2012.49101 |
| [21] | Kulis D, Bottomley A, Velikova G, et al. (2017) EORTC Quality of Life Group Translation Procedure 2017. Brussels: EORTC Quality of Life Group. [cited 2024 October 01]. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/translation_manual_2017.pdf. |
| [22] |
Maslach C, Leiter MP (2016) Understanding the burnout experience: Recent research and its implications for psychiatry. World Psychiatry 15: 103-111. https://doi.org/10.1002/wps.20311
|
| [23] |
Dugani S, Afari H, Hirschhorn LR, et al. (2018) Prevalence and factors associated with burnout among frontline primary health care providers in low- and middle-income countries: A systematic review. Gates Open Res 2: 4. https://doi.org/10.12688/gatesopenres.12779.1
|
| [24] |
Ge MW, Hu FH, Jia YJ, et al. (2023) Global prevalence of nursing burnout syndrome and temporal trends for the last 10 years: A meta-analysis of 94 studies covering over 30 countries. J Clin Nurs 32: 5836-5854. https://doi:10.1111/jocn.16708
|
| [25] |
Shanafelt TD, Gorringe G, Menaker R, et al. (2015) Impact of organizational leadership on physician burnout and satisfaction. Mayo Clin Proc 90: 432-440. https://doi.org/10.1016/j.mayocp.2015.01.012
|
| [26] |
Del Carmen MG, Herman J, Rao S, et al. (2019) Trends and factors associated with physician burnout at a multispecialty academic faculty practice organization. JAMA Netw open 2: e190554. https://doi:10.1001/jamanetworkopen.2019.0554
|
| [27] |
Tang L, Pang Y, He Y, et al. (2018) Burnout among early-career oncology professionals and the risk factors. Psychooncology 27: 2436-2441. https://doi.org/10.1002/pon.4847
|
| [28] |
Gerber M, Schilling R, Colledge F, et al. (2020) More than a simple pastime? The potential of physical activity to moderate the relationship between occupational stress and burnout symptoms. Int J Stress Manage 27: 53-64. https://doi:10.1037/str0000129
|
| [29] |
Shanafelt TD, Hasan O, Dyrbye LN, et al. (2019) Changes in burnout and satisfaction with work-life integration in physicians and the general US working population between 2011 and 2017. Mayo Clin Proc 94: 1681-1694. https://doi.org/10.1016/j.mayocp.2018.10.023
|
| [30] |
Fendel JC, Bürkle JJ, Göritz AS (2019) Mindfulness-based interventions to reduce burnout and stress in physicians: A study protocol for a systematic review and meta-analysis. BMJ Open 9: e032295. https://doi.org/10.1136/bmjopen-2019-032295
|
| [31] |
Adam D, Gonçalves F, Lavigne N, et al. (2023) Interventions to reduce stress and prevent burnout in healthcare professionals supported by digital applications: A scoping review. Front Public Health 11: 1231266. https://doi.org/10.3389/fpubh.2023.1231266
|
| [32] |
Hlubocky FJ, Rose M, Epstein RM (2017) Mastering resilience in oncology: Learn to thrive in the face of burnout. Am Soc Clin Oncol Educ B 37: 771-781. https://doi.org/10.14694/edbk_173874
|
| [33] |
West CP, Dyrbye LN, Erwin PJ, et al. (2016) Interventions to prevent and reduce physician burnout: A systematic review and meta-analysis. Lancet 388: 2272-2281. https://doi.org/10.1016/S0140-6736(16)31279-X
|
| [34] |
Salyers MP, Bonfils KA, Luther L, et al. (2019) A comparative effectiveness trial to reduce burnout and improve quality of care. Adm Policy Ment Health Ment Health Serv Res 46: 238-254. https://doi.org/10.1007/s10488-018-0908-4
|
| [35] | Bonumwezi J, Soffer R, Spira PEG (2022) Addressing clinician burnout in a community mental health setting during the COVID pandemic. Behav Health News . [cited 2024 October 01]. Available from: https://behavioralhealthnews.org/addressing-clinician-burnout-in-a-community-mental-health-setting-during-the-covid-pandemic/ |
| [36] |
Gonçalves F, Gaudencio M, Castelo Branco M, et al. (2024) Burnout and attachment in oncology and palliative care healthcare professionals. BMJ Support Palliat Care 14: e2843-e2855. https://doi:10.1136/spcare-2023-004694
|
| [37] |
Smaliukienè R, Bekesiene S, Hoskova-Mayerova S (2024) Editorial: Emotional resilience for wellbeing and employability: The role of learning and training. Front Psychol 15: 1379696. https://doi:10.3389/fpsyg.2024.1379696
|
| [38] |
Moss M, Good VS, Gozal D, et al. (2016) An official critical care societies collaborative statement: Burnout syndrome in critical care healthcare professionals: A call for action. Crit Care Med 44: 1414-1421. https://doi.org/10.1097/CCM.0000000000001885
|
| [39] | (2019) National Academies of Sciences, Engineering, and MedicineTaking action against clinician burnout: A systems approach to professional well-being. Washington, DC: National Academies Press. [cited 2024 September 23]. Available from: https://books.google.jo/books?hl = en&lr = &id = cnHJDwAAQBAJ&oi = fnd&pg = PR1. |
| 1. | Dody Dwi Handoko, Anisa Maharani Kaseh, Laras Cempaka, Wahyudi David, Bram Kusbiantoro, Afifah Zahra Agista, Yusuke Ohsaki, Hitoshi Shirakawa, , Effects of household-scale cooking on volatile compounds, sensory profile, and hypotensive effect of Kenikir (Cosmos caudatus), 2023, 8, 2471-2086, 198, 10.3934/agrfood.2023011 | |
| 2. | A Short Review: Bioactivity of Fermented Rice Bran, 2021, 70, 1345-8957, 1565, 10.5650/jos.ess21190 | |
| 3. | Slamet BUDIJANTO, Lilis NURAIDA, Bambang Pontjo PRIOSOERYANTO, Uus SAEPULOH, Sela Septima MARYA, Hitoshi SHIRAKAWA, Fermented black rice bran extract inhibit colon cancer proliferation in WiDr cell lines, 2022, 42, 1678-457X, 10.1590/fst.14422 | |
| 4. | Yanping Chi, Lining Kang, Xiangying Liu, Hongrui Sun, Yue Meng, Jialin Zhang, You Kang, Yonggang Dai, Preparation, Purification, Characterization and Antioxidant Activity of Rice Bran Fermentation Broth with Hypsizigus marmoreus, 2024, 10, 2311-5637, 188, 10.3390/fermentation10040188 | |
| 5. | Kenneth Prudence Abasubong, Ndakalimwe Naftal Gabriel, Jean-Jacques Yao Adjoumani, 2024, Chapter 11, 978-981-97-4278-3, 243, 10.1007/978-981-97-4279-0_11 |
Figures(2) / Tables(4)
Omar Shamieh, Waleed Alrjoub, Ghadeer Alarjeh, Khawlah Ammar, Mohammad Abu Hazim, Tayseer Shawash, Osama Zamel, Maysa Al-Hussaini, Majeda Al-Ruzzieh, Hikmat Abdel-Razeq, Asem Mansour. Prevalence and predictors of staff burnout at a tertiary cancer center in Jordan[J]. AIMS Public Health, 2025, 12(2): 470-490. doi: 10.3934/publichealth.2025026
| Group | 0 h | 2 h | 4 h | 6 h |
| Control | 172.3 ± 13.1 | 172.0 ± 8.1 | 161.3 ± 6.5 | 168.0 ± 3.0 |
| CIF | 176.8 ± 9.1 | 175.3 ± 2.9 | 165.3 ± 13.3 | 166.8 ± 8.5 |
| Change b (%) | - | +1.9 | +2.4 | −0.7 |
| IPRF | 171.3 ± 5.0 | 152.3 ± 14.3 | 142.0 ± 12.4 | 141.5 ± 12.2* |
| Change b (%) | - | −12.9 | −13.6 | −18.7 |
| Note: a Values are given as means ± SD, n = 4. *A significantly different (p < 0.05) versus Control after statistical analysis by one-way analysis of variance using SPSS version 22 software (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test. | ||||
DownLoad:
CSV
| Compounds | Codes | HMDB ID | Relative Concentrations (ppm) | Effects | References | |||
| Inpari 30 | Cempo Ireng | |||||||
| Non-fermented | Fermented | Non-fermented | Fermented | |||||
| (Amino acids) | ||||||||
| Meta-tyrosine | AA1 | 0059720 | ND | 0.0266* | ND | ND | Immunoprotective | [41] |
| Reduces metastasis | [42] | |||||||
| Norvaline | AA2 | 0013716 | 0.0253* | 0.0008* | ND | ND | Arginase inhibitor | [31] |
| N-Acetyltryptophan | AA3 | 0013713 | ND | 0.0039* | ND | ND | Antioxidant | [43] |
| 1H-Imidazole-1-acetic acid | AA4 | 0029736 | ND | ND | ND | 0.0033* | - | - |
| L-DOPA | AA5 | 0000181 | ND | ND | ND | 0.0050* | Treatment of Parkinson Dissease (by increasing dopamine levels in brain) | [44] |
| 3-Methyldioxyindole | AA6 | 0004186 | ND | ND | 0.0011 ± 0.0003 | ND | - | - |
| L-Phenylalanine | AA7 | 0000159 | ND | 0.2413 ± 0.2051a | ND | 0.0360 ± 0.0080b | Neurotransmitter synthesis, hormones and pigments synthesis | [26] |
| Indoleacrylic acid | AA8 | 0000734 | 0.0115*a | 0.1806 ± 0.1412b | ND | 0.0395 ± 0.0011a | Improves the instentines functions | [45] |
| (Carbohydrates) | ||||||||
| Succinic acid | KH | 0000254 | 0.0002* | ND | ND | ND | Antioxidant, Imrpove the immune and nervous functions | [46] |
| (Lipids) | ||||||||
| Cincassiol B | LD1 | 0036855 | ND | 0, 0208* | ND | ND | - | - |
| Lacinilene C 7-methyl ether | LD2 | 0036456 | 0.0129 ± 0.0015 | 0.0058* | 0.0134* | 0.0023* | Antimicrobial | [22] |
| Valdiic acid | LD3 | 0040980 | ND | 0.0088 ± 0.0108 | ND | ND | - | - |
| Prostaglandin C1(1-) | LD4 | 0062756 | 0.0102 ± 0.0029 | ND | 0.0090 ± 0.0017 | ND | - | - |
| 10-Oxo-11-octadecen-13-olide | LD5 | 0029786 | 0.0041* | ND | 0.0109* | ND | - | - |
| Aminocaproic acid | LD6 | 0001901 | ND | 0.0390* | ND | 0.0037* | Antifibrinolytic | [47] |
| L-Octanoylcarnitine | LD7 | 0000791 | ND | 0.0180* | 0.0091 ± 0.0052 | ND | - | - |
| Leukotriene A4 | LD8 | 0029016 | 0.0352 ± 0.0288 | 0.0131 ± 0.0063 | 0.0110* | ND | The parent molecule for the biosynthesis of all leukotrienes | [48] |
| Phytosphingosine | LD9 | 0004610 | ND | 0.0126*b | 0.0114 ± 0.0031a | 0.0049 ± 0.0042b | ● Anti-inlammatory and antibacterial in skin disorders | [31] |
| ● Activates the transcription activity on PPAR | [23] | |||||||
| (Ent-2alpha, 3beta, 15beta, 16beta)-15, 16-Epoxy-2, 3-kauranediol | LD10 | 0038688 | 0.0201 ± 0.0099b | ND | 0.0019*a | ND | - | - |
| Dehydroabietic acid | LD11 | 0031127 | 0.0263* | ND | ND | ND | ● Anti-inflammatory in obese people | [49] |
| ● Activates the SIRT1 enzymes | [50] | |||||||
| 13, 14-Dihydro-15-keto-PGE2 | LD12 | 0002776 | ND | ND | 0.0010* | ND | Increases the growth of pancreatic celss | [51] |
| 3-hydroxyundecanoyl carnitine | LD13 | 0061637 | ND | ND | 0.0102 ± 0.0031 | ND | - | - |
| Leukotriene C4 | LD14 | 0001198 | 0.0095* | ND | ND | ND | Lipid mediator for inflammation | [52] |
| 5-Hexyltetrahydro-2-furanoctanoic acid | LD15 | 0029018 | 0.0105* | ND | 0.0021* | ND | - | - |
| (Z)-13-Oxo-9-octadecenoic acid | LD16 | 0029796 | 0.0094* | 0.0072* | ND | ND | - | - |
| (Nucleotides) | ||||||||
| Adenosine | NA | 0000050 | 0.0838 ± 0.1053 | 0.4323 ± 0.1236 | 0.2119 ± 0.0142 | 0.3007 ± 0.1602 | ● Neuromodulator | [34] |
| ● Neuroprotective | [33] | |||||||
| ● Reduces epilepsy | [32] | |||||||
| ● Regulates the sleep cycle | [53] | |||||||
| ● Lowering blood pressure | [5] | |||||||
| (Secondary Metabolites) | ||||||||
| Cohumulone | MS1 | 0033981 | ND | 0.0052* | ND | ND | Aldo keto reductase inhibitors | [54] |
| 3-O-Methylmethyldopa | MS2 | 0142154 | ND | 0.0022 ± 0.0005 | ND | ND | - | - |
| 2, 6-Dimethoxy-4-propylphenol | MS3 | 0036226 | ND | 0.0007 ± 0.0001 | ND | ND | - | - |
| Alpha-curcumene | MS4 | 0059878 | ND | 0.0017±0.0004 | ND | ND | ● Antimicrobial | [55] |
| ● Induced apoptosis | [56] | |||||||
| Cuscohygrine | MS5 | 0030290 | ND | 0.0033* | 0.0051* | 0.0028* | - | - |
| 3-Tert-butyl-4-hydroxyanisole | MS6 | 0059925 | ND | 0.0015* | 0.0184* | ND | The building blocks of butylated hydroxyanisole (BHA) | [57] |
| Momilactone B | MS7 | 0036749 | ND | 0.0153* | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| ● Cancer chemopreventive | [19] | |||||||
| 2-Indolecarboxylic acid | MS8 | 0002285 | 0.0024* | ND | 0.0023* | ND | Antioxidant | [58] |
| Kojic acid | MS9 | 0032923 | 0.0061 ± 0.0016 | ND | 0.0103 ± 0.0010 | ND | ● Tyrosinase inhibitors | [59] |
| ● Immunomodulator | [9] | |||||||
| L-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid | MS10 | 0035665 | 0.0008* | ND | ND | ND | - | - |
| 4-Methylbenzoic acid | MS11 | 0029635 | 0.0010*a | ND | ND | 0.0385 ± 0.0103b | - | - |
| 2-Methylhippuric acid | MS12 | 0011723 | 0.0006* | ND | ND | ND | - | - |
| Momilactone A | MS13 | 0036748 | 0.0020* | ND | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| Coumarin | MS14 | 0001218 | 0.0009* | ND | ND | ND | ● Antimicrobial | [60) |
| ● Acetylcholinesterase (AChE) inhibitor | [61] | |||||||
| Quercetin | MS15 | 0005794 | ND | ND | 0.0050 ± 0.0031 | 0.0057 ± 0.0028 | ● Antioxidant | [62] |
| ● Decreases activation of dendytic celss for the treatment of inflammation, autoimmunity and transplantation | [61] | |||||||
| ● Antiviral activity against dengue fever | [63] | |||||||
| ● Lowering blood pressure in people with hypertension | [64] | |||||||
| ● Reduces symptoms of non-alcoholic fatty liver dissease | [65] | |||||||
| Isorhamnetin 7-glucoside | MS16 | 0029479 | ND | ND | 0.0089 ± 0.0050 | 0.0165 ± 0.0009 | Antioxidant | [66] |
| Isorhamnetin | MS17 | 0002655 | ND | ND | 0.0048* | 0.0121* | Treats cerebral vascular complications associated with diabetes | [67] |
| 2-Hydroxy-2-phenylpropanoic acid | MS18 | 0142137 | ND | ND | 0.0045 ± 0.0007a | 0.0029 ± 0.0013b | - | - |
| 2-Phenylpropionaldehyde dimethyl acetal | MS19 | 0032468 | ND | ND | ND | 0.0055 ± 0.0022 | - | - |
| Naringenin | MS20 | 0002670 | ND | ND | ND | 0.0037* | ● Hepatoprotector | [68] |
| ● Reduces TNF- α production | [69] | |||||||
| ● Anti-hyperglycemia | [70] | |||||||
| ● Cardioprotective | [71] | |||||||
| ● Antiviral activity against dengue fever | [72] | |||||||
| ● Inhibits the proliferation and migration of prostate cancer cells | [73] | |||||||
| Phenprocoumon | MS21 | 0015081 | ND | ND | ND | 0.0058* | ● Anticoagulant | [74] |
| Isovanillic acid | MS22 | 0060003 | ND | ND | 0.0042 ± 0.0011 | ND | ● Antibacterial | [75] |
| ● Antioxidant | [76] | |||||||
| Antimicrobial | [60] | |||||||
| 2, 6-Dimethoxybenzoic acid | MS23 | 0029273 | ND | ND | 0.0106* | ND | - | - |
| Benzoic acid | MS24 | 0001870 | ND | ND | 0.0009 ± 0.0003 | ND | Inhibits the growth of resistant bacteria | [77] |
| N, N-diethyl phenylacetamide | MS25 | 0032635 | 0.0090* | 0.0096* | 0.0066* | 0.0263* | Mosquitos repellent | [17] |
| Oryzalide B | MS27 | 0037592 | ND | ND | ND | 0.0053 ± 0.0032 | Antibacterial | [78] |
| Acetylvalerenolic acid | MS28 | 0035687 | ND | ND | ND | 0.0045* | - | - |
| MS29 | 0035882 | ND | 0.0309 | ND | ND | Hepatoprotector | [18] | |
| Dimboa-glc | MS30 | 0029710 | ND | ND | 0.0089 ± 0.0056 | ND | - | - |
| 2-Decylfuran | MS31 | 0032215 | ND | ND | ND | 0.0015 | - | - |
| Piperenol A triacetate | MS32 | 0041535 | ND | 0.0129* | ND | ND | - | - |
| Ginsenoyne G | MS33 | 0039589 | ND | ND | 0.0025 | ND | - | - |
| Acetylpterosin C | MS34 | 0030764 | 0.0053* | ND | ND | ND | - | - |
| 1, 3, 11-Tridecatriene-5, 7, 9-triyne | MS35 | 0034294 | ND | ND | 0.0160 | ND | - | - |
| Myrigalone A | MS36 | 0037245 | ND | ND | 0.0278* | 0.0256* | Antibacterial | [79] |
| (Vitamins dan cofactors) | ||||||||
| Nicotinic acid | VK1 | 0001488 | 0.0114 ± 0.0007 | ND | 0.0060 ± 0.0025 | 0.0076 ± 0.0009 | Increases HDL cholesterol and lowers triglycerides for the treatment of atherosclerosis | [29] |
| Pantothenic acid | VK2 | 0000210 | ND | ND | ND | 0.0028 ± 0.0010 | Substrates for the synthesis of coenzyme A and ACP (acyl carrier protein) | [80] |
| 2-Hydroxypyridine | VK3 | 0013751 | 0.0008* | ND | ND | ND | - | - |
| 4-Methyl-5-thiazoleethanol | VK4 | - | 0.0175 ± 0.0014 | ND | 0.0066 ± 0.0021 | ND | - | - |
| Trigonelline | VK5 | 0000875 | 0.0344 ± 0.0247 | ND | ND | ND | ● Increases cell sensitivity to anticancer and apoptotic drugs | [81] |
| ● Prevents gastric ulcer induced by indomethacin | [82] | |||||||
| ● Lowering blood sugar and lipid as well as increasing insulin sensitivity for diabetes | ||||||||
| ● Inhibits neurons loss in hypocampus | [83] | |||||||
| 7-Aminomethyl-7-carbaguanine | VK6 | 0011690 | ND | ND | ND | 0.0132* | - | - |
| Pyridoxal | VK7 | 0001545 | ND | ND | 0.0066 ± 0.0021 | ND | ● Cofactors in various amino acids metabolism | [84] |
| ● Maintains the nervous systems in infants | [85] | |||||||
| (Peptides) | ||||||||
| Leucyl-valine | PD1 | 0028942 | ND | 0.0222 ± 0.0162 | ND | ND | Increases the expression of glutathione peroxidase, antioxidants and cell protection agents | [86] |
| Leucyl-isoleucine | PD2 | 0028932 | ND | 0.0653 ± 0.0436 | ND | 0.0596 ± 0.0263 | Increases the stimulation of AMPK phosphorylation (5'-AMP protein kinase), monocytes, and platelets | [30] |
| Note: The presentation of the relative value data for the compounds comes from the calculation of the average relative area of the compound from 3 replications ± deviation standard; ND = Not Detected; * = compound obtained only in 1 replication; Numbers on the same line with different letters indicate significant differences (p < 0.05). | ||||||||
DownLoad:
CSV
| Group | 0 h | 2 h | 4 h | 6 h |
| Control | 172.3 ± 13.1 | 172.0 ± 8.1 | 161.3 ± 6.5 | 168.0 ± 3.0 |
| CIF | 176.8 ± 9.1 | 175.3 ± 2.9 | 165.3 ± 13.3 | 166.8 ± 8.5 |
| Change b (%) | - | +1.9 | +2.4 | −0.7 |
| IPRF | 171.3 ± 5.0 | 152.3 ± 14.3 | 142.0 ± 12.4 | 141.5 ± 12.2* |
| Change b (%) | - | −12.9 | −13.6 | −18.7 |
| Note: a Values are given as means ± SD, n = 4. *A significantly different (p < 0.05) versus Control after statistical analysis by one-way analysis of variance using SPSS version 22 software (SPSS, Inc., Chicago, IL, USA) followed by Duncan's multiple range test. | ||||
| Compounds | Codes | HMDB ID | Relative Concentrations (ppm) | Effects | References | |||
| Inpari 30 | Cempo Ireng | |||||||
| Non-fermented | Fermented | Non-fermented | Fermented | |||||
| (Amino acids) | ||||||||
| Meta-tyrosine | AA1 | 0059720 | ND | 0.0266* | ND | ND | Immunoprotective | [41] |
| Reduces metastasis | [42] | |||||||
| Norvaline | AA2 | 0013716 | 0.0253* | 0.0008* | ND | ND | Arginase inhibitor | [31] |
| N-Acetyltryptophan | AA3 | 0013713 | ND | 0.0039* | ND | ND | Antioxidant | [43] |
| 1H-Imidazole-1-acetic acid | AA4 | 0029736 | ND | ND | ND | 0.0033* | - | - |
| L-DOPA | AA5 | 0000181 | ND | ND | ND | 0.0050* | Treatment of Parkinson Dissease (by increasing dopamine levels in brain) | [44] |
| 3-Methyldioxyindole | AA6 | 0004186 | ND | ND | 0.0011 ± 0.0003 | ND | - | - |
| L-Phenylalanine | AA7 | 0000159 | ND | 0.2413 ± 0.2051a | ND | 0.0360 ± 0.0080b | Neurotransmitter synthesis, hormones and pigments synthesis | [26] |
| Indoleacrylic acid | AA8 | 0000734 | 0.0115*a | 0.1806 ± 0.1412b | ND | 0.0395 ± 0.0011a | Improves the instentines functions | [45] |
| (Carbohydrates) | ||||||||
| Succinic acid | KH | 0000254 | 0.0002* | ND | ND | ND | Antioxidant, Imrpove the immune and nervous functions | [46] |
| (Lipids) | ||||||||
| Cincassiol B | LD1 | 0036855 | ND | 0, 0208* | ND | ND | - | - |
| Lacinilene C 7-methyl ether | LD2 | 0036456 | 0.0129 ± 0.0015 | 0.0058* | 0.0134* | 0.0023* | Antimicrobial | [22] |
| Valdiic acid | LD3 | 0040980 | ND | 0.0088 ± 0.0108 | ND | ND | - | - |
| Prostaglandin C1(1-) | LD4 | 0062756 | 0.0102 ± 0.0029 | ND | 0.0090 ± 0.0017 | ND | - | - |
| 10-Oxo-11-octadecen-13-olide | LD5 | 0029786 | 0.0041* | ND | 0.0109* | ND | - | - |
| Aminocaproic acid | LD6 | 0001901 | ND | 0.0390* | ND | 0.0037* | Antifibrinolytic | [47] |
| L-Octanoylcarnitine | LD7 | 0000791 | ND | 0.0180* | 0.0091 ± 0.0052 | ND | - | - |
| Leukotriene A4 | LD8 | 0029016 | 0.0352 ± 0.0288 | 0.0131 ± 0.0063 | 0.0110* | ND | The parent molecule for the biosynthesis of all leukotrienes | [48] |
| Phytosphingosine | LD9 | 0004610 | ND | 0.0126*b | 0.0114 ± 0.0031a | 0.0049 ± 0.0042b | ● Anti-inlammatory and antibacterial in skin disorders | [31] |
| ● Activates the transcription activity on PPAR | [23] | |||||||
| (Ent-2alpha, 3beta, 15beta, 16beta)-15, 16-Epoxy-2, 3-kauranediol | LD10 | 0038688 | 0.0201 ± 0.0099b | ND | 0.0019*a | ND | - | - |
| Dehydroabietic acid | LD11 | 0031127 | 0.0263* | ND | ND | ND | ● Anti-inflammatory in obese people | [49] |
| ● Activates the SIRT1 enzymes | [50] | |||||||
| 13, 14-Dihydro-15-keto-PGE2 | LD12 | 0002776 | ND | ND | 0.0010* | ND | Increases the growth of pancreatic celss | [51] |
| 3-hydroxyundecanoyl carnitine | LD13 | 0061637 | ND | ND | 0.0102 ± 0.0031 | ND | - | - |
| Leukotriene C4 | LD14 | 0001198 | 0.0095* | ND | ND | ND | Lipid mediator for inflammation | [52] |
| 5-Hexyltetrahydro-2-furanoctanoic acid | LD15 | 0029018 | 0.0105* | ND | 0.0021* | ND | - | - |
| (Z)-13-Oxo-9-octadecenoic acid | LD16 | 0029796 | 0.0094* | 0.0072* | ND | ND | - | - |
| (Nucleotides) | ||||||||
| Adenosine | NA | 0000050 | 0.0838 ± 0.1053 | 0.4323 ± 0.1236 | 0.2119 ± 0.0142 | 0.3007 ± 0.1602 | ● Neuromodulator | [34] |
| ● Neuroprotective | [33] | |||||||
| ● Reduces epilepsy | [32] | |||||||
| ● Regulates the sleep cycle | [53] | |||||||
| ● Lowering blood pressure | [5] | |||||||
| (Secondary Metabolites) | ||||||||
| Cohumulone | MS1 | 0033981 | ND | 0.0052* | ND | ND | Aldo keto reductase inhibitors | [54] |
| 3-O-Methylmethyldopa | MS2 | 0142154 | ND | 0.0022 ± 0.0005 | ND | ND | - | - |
| 2, 6-Dimethoxy-4-propylphenol | MS3 | 0036226 | ND | 0.0007 ± 0.0001 | ND | ND | - | - |
| Alpha-curcumene | MS4 | 0059878 | ND | 0.0017±0.0004 | ND | ND | ● Antimicrobial | [55] |
| ● Induced apoptosis | [56] | |||||||
| Cuscohygrine | MS5 | 0030290 | ND | 0.0033* | 0.0051* | 0.0028* | - | - |
| 3-Tert-butyl-4-hydroxyanisole | MS6 | 0059925 | ND | 0.0015* | 0.0184* | ND | The building blocks of butylated hydroxyanisole (BHA) | [57] |
| Momilactone B | MS7 | 0036749 | ND | 0.0153* | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| ● Cancer chemopreventive | [19] | |||||||
| 2-Indolecarboxylic acid | MS8 | 0002285 | 0.0024* | ND | 0.0023* | ND | Antioxidant | [58] |
| Kojic acid | MS9 | 0032923 | 0.0061 ± 0.0016 | ND | 0.0103 ± 0.0010 | ND | ● Tyrosinase inhibitors | [59] |
| ● Immunomodulator | [9] | |||||||
| L-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid | MS10 | 0035665 | 0.0008* | ND | ND | ND | - | - |
| 4-Methylbenzoic acid | MS11 | 0029635 | 0.0010*a | ND | ND | 0.0385 ± 0.0103b | - | - |
| 2-Methylhippuric acid | MS12 | 0011723 | 0.0006* | ND | ND | ND | - | - |
| Momilactone A | MS13 | 0036748 | 0.0020* | ND | ND | ND | ● α-Amylase and α-Glucosidase inhibitors | [20] |
| Coumarin | MS14 | 0001218 | 0.0009* | ND | ND | ND | ● Antimicrobial | [60) |
| ● Acetylcholinesterase (AChE) inhibitor | [61] | |||||||
| Quercetin | MS15 | 0005794 | ND | ND | 0.0050 ± 0.0031 | 0.0057 ± 0.0028 | ● Antioxidant | [62] |
| ● Decreases activation of dendytic celss for the treatment of inflammation, autoimmunity and transplantation | [61] | |||||||
| ● Antiviral activity against dengue fever | [63] | |||||||
| ● Lowering blood pressure in people with hypertension | [64] | |||||||
| ● Reduces symptoms of non-alcoholic fatty liver dissease | [65] | |||||||
| Isorhamnetin 7-glucoside | MS16 | 0029479 | ND | ND | 0.0089 ± 0.0050 | 0.0165 ± 0.0009 | Antioxidant | [66] |
| Isorhamnetin | MS17 | 0002655 | ND | ND | 0.0048* | 0.0121* | Treats cerebral vascular complications associated with diabetes | [67] |
| 2-Hydroxy-2-phenylpropanoic acid | MS18 | 0142137 | ND | ND | 0.0045 ± 0.0007a | 0.0029 ± 0.0013b | - | - |
| 2-Phenylpropionaldehyde dimethyl acetal | MS19 | 0032468 | ND | ND | ND | 0.0055 ± 0.0022 | - | - |
| Naringenin | MS20 | 0002670 | ND | ND | ND | 0.0037* | ● Hepatoprotector | [68] |
| ● Reduces TNF- α production | [69] | |||||||
| ● Anti-hyperglycemia | [70] | |||||||
| ● Cardioprotective | [71] | |||||||
| ● Antiviral activity against dengue fever | [72] | |||||||
| ● Inhibits the proliferation and migration of prostate cancer cells | [73] | |||||||
| Phenprocoumon | MS21 | 0015081 | ND | ND | ND | 0.0058* | ● Anticoagulant | [74] |
| Isovanillic acid | MS22 | 0060003 | ND | ND | 0.0042 ± 0.0011 | ND | ● Antibacterial | [75] |
| ● Antioxidant | [76] | |||||||
| Antimicrobial | [60] | |||||||
| 2, 6-Dimethoxybenzoic acid | MS23 | 0029273 | ND | ND | 0.0106* | ND | - | - |
| Benzoic acid | MS24 | 0001870 | ND | ND | 0.0009 ± 0.0003 | ND | Inhibits the growth of resistant bacteria | [77] |
| N, N-diethyl phenylacetamide | MS25 | 0032635 | 0.0090* | 0.0096* | 0.0066* | 0.0263* | Mosquitos repellent | [17] |
| Oryzalide B | MS27 | 0037592 | ND | ND | ND | 0.0053 ± 0.0032 | Antibacterial | [78] |
| Acetylvalerenolic acid | MS28 | 0035687 | ND | ND | ND | 0.0045* | - | - |
| MS29 | 0035882 | ND | 0.0309 | ND | ND | Hepatoprotector | [18] | |
| Dimboa-glc | MS30 | 0029710 | ND | ND | 0.0089 ± 0.0056 | ND | - | - |
| 2-Decylfuran | MS31 | 0032215 | ND | ND | ND | 0.0015 | - | - |
| Piperenol A triacetate | MS32 | 0041535 | ND | 0.0129* | ND | ND | - | - |
| Ginsenoyne G | MS33 | 0039589 | ND | ND | 0.0025 | ND | - | - |
| Acetylpterosin C | MS34 | 0030764 | 0.0053* | ND | ND | ND | - | - |
| 1, 3, 11-Tridecatriene-5, 7, 9-triyne | MS35 | 0034294 | ND | ND | 0.0160 | ND | - | - |
| Myrigalone A | MS36 | 0037245 | ND | ND | 0.0278* | 0.0256* | Antibacterial | [79] |
| (Vitamins dan cofactors) | ||||||||
| Nicotinic acid | VK1 | 0001488 | 0.0114 ± 0.0007 | ND | 0.0060 ± 0.0025 | 0.0076 ± 0.0009 | Increases HDL cholesterol and lowers triglycerides for the treatment of atherosclerosis | [29] |
| Pantothenic acid | VK2 | 0000210 | ND | ND | ND | 0.0028 ± 0.0010 | Substrates for the synthesis of coenzyme A and ACP (acyl carrier protein) | [80] |
| 2-Hydroxypyridine | VK3 | 0013751 | 0.0008* | ND | ND | ND | - | - |
| 4-Methyl-5-thiazoleethanol | VK4 | - | 0.0175 ± 0.0014 | ND | 0.0066 ± 0.0021 | ND | - | - |
| Trigonelline | VK5 | 0000875 | 0.0344 ± 0.0247 | ND | ND | ND | ● Increases cell sensitivity to anticancer and apoptotic drugs | [81] |
| ● Prevents gastric ulcer induced by indomethacin | [82] | |||||||
| ● Lowering blood sugar and lipid as well as increasing insulin sensitivity for diabetes | ||||||||
| ● Inhibits neurons loss in hypocampus | [83] | |||||||
| 7-Aminomethyl-7-carbaguanine | VK6 | 0011690 | ND | ND | ND | 0.0132* | - | - |
| Pyridoxal | VK7 | 0001545 | ND | ND | 0.0066 ± 0.0021 | ND | ● Cofactors in various amino acids metabolism | [84] |
| ● Maintains the nervous systems in infants | [85] | |||||||
| (Peptides) | ||||||||
| Leucyl-valine | PD1 | 0028942 | ND | 0.0222 ± 0.0162 | ND | ND | Increases the expression of glutathione peroxidase, antioxidants and cell protection agents | [86] |
| Leucyl-isoleucine | PD2 | 0028932 | ND | 0.0653 ± 0.0436 | ND | 0.0596 ± 0.0263 | Increases the stimulation of AMPK phosphorylation (5'-AMP protein kinase), monocytes, and platelets | [30] |
| Note: The presentation of the relative value data for the compounds comes from the calculation of the average relative area of the compound from 3 replications ± deviation standard; ND = Not Detected; * = compound obtained only in 1 replication; Numbers on the same line with different letters indicate significant differences (p < 0.05). | ||||||||
